Company Insights

EXEL customer relationships

Explore interactive graphBrowse insights index
EXEL customer relationship map

Exelixis’ customer map: who pays for cabozantinib and why it matters to investors

Exelixis is an oncology-focused biopharma that monetizes primarily through product sales of cabozantinib (branded CABOMETYX and COMETRIQ) to specialty distributors and specialty pharmacies, and through collaboration royalties and development reimbursements with international partners. Revenue is recognized at a point in time on product delivery, and a concentrated set of large pharmacy distributors and specialty pharmacies account for a material share of the company’s topline. Investors should evaluate Exelixis through the twin lenses of customer concentration and partner-dependent international commercialization, both of which drive revenue volatility and upside.
For a concise enterprise view and customer-risk monitoring, visit https://nullexposure.com/.

How Exelixis sells and where the risks concentrate

Exelixis operates as a seller of finished oncology products into a classic specialty-distribution channel: products are sold to specialty distributors and specialty pharmacies and recognized upon delivery, not under long-term service contracts. That contracting posture produces cash flow tied to shipments and channel inventory turns rather than multi-year contracted revenues. According to Exelixis’ FY2026 10‑K filing (filed Jan 2, 2026), CABOMETYX sales account for the majority of company revenues, making the commercial success of cabozantinib central to growth. The company reports most revenue in the U.S. while simultaneously leveraging partners to commercialize cabozantinib overseas, creating a mix of domestic concentration and global partner dependency (FY2026 10‑K).

  • Contracting posture: spot product sales recognized at point of delivery (FY2026 10‑K).
  • Customer mix: specialty distributors and specialty pharmacies are primary customers; government payers (Medicare/Medicaid) influence market acceptance and reimbursement (FY2026 10‑K).
  • Geography: predominantly U.S. revenue, with global approvals and partner-driven international sales (FY2026 10‑K and corporate press).
  • Materiality: cabozantinib is a critical, core-product driver of Exelixis’ cash flows and growth (FY2026 10‑K).

For ongoing tracking of customer concentrations and partner exposure, see https://nullexposure.com/.

Customer roster — line-by-line takeaways

Below are every customer/partner relationship referenced in Exelixis’ FY2026 disclosures and recent press mentions, presented with plain-English summaries and source attribution.

Accredo Health Incorporated

Accredo is listed as a customer accounting for 12% of Exelixis’ trade receivables, indicating a sizeable receivable exposure to this specialty pharmacy/distribution arm. Source: Exelixis FY2026 10‑K (filed Jan 2, 2026).

Accredo Health, Incorporated (duplicate mention)

The filing repeats Accredo’s 12% representation among significant customers, underscoring the concentration in specialty-pharmacy channels. Source: Exelixis FY2026 10‑K (FY2026).

Affiliates of Cencora Inc.

Affiliates of Cencora accounted for 22% of total revenues, making Cencora the single largest customer grouping disclosed and a key counterparty for collections and pricing negotiations. Source: Exelixis FY2026 10‑K (FY2026).

Affiliates of CVS Health Corporation

Affiliates of CVS Health are reported as representing 15% of Exelixis’ total revenues, reflecting meaningful exposure to a major pharmacy-benefit manager and specialty pharmacy channel. Source: Exelixis FY2026 10‑K (FY2026).

Affiliates of McKesson Corporation

Affiliates of McKesson represented 19% of total revenues, placing McKesson among the top few distributors driving Exelixis’ product flow into the U.S. market. Source: Exelixis FY2026 10‑K (FY2026).

Affiliates of Optum Specialty Pharmacy

Affiliates of Optum Specialty Pharmacy are reported at 10% of total revenues, signaling Optum’s material role in dispensing and payer-channel relationships for Exelixis products. Source: Exelixis FY2026 10‑K (FY2026).

Cardinal Health, Inc.

Cardinal Health accounted for 12% of Exelixis’ trade receivables, highlighting another large distributor counterparty that affects working capital and credit exposure. Source: Exelixis FY2026 10‑K (FY2026).

Cencora, Inc.

Cencora is cited directly as contributing 22% of total revenues, reiterating the concentration disclosed under “Affiliates of Cencora.” This underscores strategic dependence on a single distributor network for a large share of sales. Source: Exelixis FY2026 10‑K (FY2026).

CVS Health Corporation

CVS Health is listed as generating 15% of total revenues, consistent with the affiliate disclosure and confirming CVS’ material position in the company’s commercial footprint. Source: Exelixis FY2026 10‑K (FY2026).

Ipsen Pharma SAS

Ipsen is a collaboration partner that sells cabozantinib outside the U.S., and Exelixis reports royalty and collaboration revenue increases tied to Ipsen’s sales; Ipsen’s role is therefore essential to Exelixis’ international revenue stream. Source: PharmiWeb press release February 11, 2026 (company results commentary).

Optum Specialty Pharmacy

Optum Specialty Pharmacy is separately identified at 10% of revenue, again underlining concentration within specialty pharmacies and the company’s reliance on a small set of dispensing organizations. Source: Exelixis FY2026 10‑K (FY2026).

McKesson Corporation (MCK)

McKesson (ticker MCK) is explicitly named as contributing 19% of total revenues, reinforcing distributor concentration risk and highlighting a counterparty that materially affects Exelixis’ revenue and receivable profile. Source: Exelixis FY2026 10‑K (FY2026).

Ipsen (news context)

Independent press coverage notes Exelixis’ partnership with Ipsen to commercialize cabozantinib in key international markets, supporting the company’s global sales and royalty stream. Source: Intellectia/financial news coverage (Mar 2026) and PharmiWeb (Feb 2026).

Takeda (news context)

Takeda is identified as an additional international partner for cabozantinib sales in Japan; Exelixis and partners collectively reported $2.9 billion in global cabozantinib franchise net product revenues in 2025, indicating the material commercial scale produced through partner networks. Source: PharmiWeb press release February 11, 2026.

What this customer profile means for investors

  • Concentration risk is high and measurable. Cencora (22%), McKesson (19%), CVS (15%) and other large specialty/pharmacy distributors together account for a substantial portion of revenue and trade receivables (Exelixis FY2026 10‑K). That concentration creates single‑counterparty exposure to pricing, reimbursement, and inventory decisions.
  • Revenue is transaction-driven and tied to channel flows. The company’s point-in-time recognition model means near-term revenue and working-capital volatility track shipments and payer acceptance rather than locked multi-year contracts (FY2026 10‑K).
  • Cabozantinib is core and critical. Exelixis’ growth and cash generation depend principally on the commercial performance of the cabozantinib franchise and partner execution outside the U.S. (FY2026 10‑K; PharmiWeb Feb 2026).
  • Payer and government exposure is meaningful. Government healthcare payers and commercial plans influence physicians’ and hospitals’ prescribing behavior and reimbursement levels, affecting realized prices and uptake (FY2026 10‑K).

For a structured view of customer concentrations and to monitor shifts in counterparty exposure over time, go to https://nullexposure.com/.

Bottom line and investor action checklist

Exelixis presents a high‑conviction commercial story built on a single, high‑performing oncology franchise sold through a concentrated set of specialty distributors and pharmacies. Investors should track: distributor/affiliate revenue shares (Cencora, McKesson, CVS, Cardinal, Optum/Accredo), reimbursement trends with U.S. government payers, and partner sales outside the U.S. that drive royalties (Ipsen, Takeda). Regularly review Exelixis’ 10‑K and partner press releases for shifts in concentration or changes to channel dynamics.

To monitor these relationship dynamics and get actionable counterparty intelligence, visit https://nullexposure.com/.